AIXC NASDAQ
AIxCrypto Holdings, Inc.
1W: -28.4%
1M: +29.0%
3M: -14.4%
YTD: -57.9%
1Y: -80.0%
3Y: -98.0%
5Y: -99.9%
$1.01
-0.65 (-39.16%)
Overview
News
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Dividends
Analysis
Technicals
Weather
Peers
ESG
Institutions
ETF Exposure
Dark Pool
Short Interest
Supply Chain
Supply Chain Overview
17 relationships17
As Filer
counterparties named
0
As Counterparty
mentioned by others
7
Rel. Types
2022-01-18
Earliest Filing
2026-02-02
Latest Filing
investor: 6
partner: 4
customer: 2
target: 2
acquirer: 1
supplier: 1
licensee: 1
Counterparties (Filed by AIXC)
17 relationshipsCompanies named in AIXC's SEC 8-K filings as business counterparties.
| Counterparty | Ticker | Relationship | Summary | Filing Date | SEC |
|---|---|---|---|---|---|
| AIxCrypto Holdings, Inc. | AIXC | acquirer | Company engaging consultant for strategic planning and crypto ecosystem services | 2026-02-02 | View |
| FF Global Partners LLC | — | supplier | Consultant providing strategic planning and crypto ecosystem services | 2026-02-02 | View |
| Faraday Future Intelligent Electric Inc. | FFAIW | investor | Led $30 million PIPE investment in Qualigen Therapeutics | 2025-10-03 | View |
| SIGN Foundation | — | investor | Blockchain technology company participating in PIPE financing | 2025-10-03 | View |
| Binance Labs | — | investor | Backed SIGN Foundation in the PIPE financing | 2025-10-03 | View |
| Sequoia Capital | — | investor | Backed SIGN Foundation in the PIPE financing | 2025-10-03 | View |
| IDG | — | investor | Backed SIGN Foundation in the PIPE financing | 2025-10-03 | View |
| Circle | CRCL | investor | Backed SIGN Foundation in the PIPE financing | 2025-10-03 | View |
| Marizyme, Inc. | — | customer | Borrower under the Amended and Restated Secured Demand Promissory Note | 2025-08-27 | View |
| Qualigen Therapeutics, Inc. | — | partner | Company entering into the placement agency agreement | 2024-09-09 | View |
| Qualigen Therapeutics, Inc. | QLGN | partner | Licensor granting exclusive and non-exclusive sublicenses of RAS technology | 2024-02-22 | View |
| Pan-RAS Holdings, Inc. | — | partner | Licensee and Sublicensee receiving rights to develop and commercialize RAS technology | 2024-02-22 | View |
| University of Louisville Research Foundation, Inc. | — | partner | Original licensor whose rights are novated to QLGN and retained as third-party beneficiary | 2024-02-22 | View |
| NanoSynex Ltd. | — | customer | Borrower receiving funding and issuing notes to Qualigen Therapeutics, Inc. | 2023-07-26 | View |
| NanoSynex Ltd. | — | target | Company receiving operational and technology funding | 2022-06-02 | View |
| NanoSynex Ltd. | — | target | Qualigen Therapeutics to acquire majority stake in Israeli-based diagnostics technology developer. | 2022-05-04 | View |
| UCL Business Limited | — | licensee | Qualigen entered into a Licence Agreement to obtain an exclusive worldwide in-license of a genomic quadruplex drug devel | 2022-01-18 | View |
Recent 8-K Filings (20)
| Filing Date | Description | Type | SEC |
|---|---|---|---|
| 2026-09-29 | Bylaws Amendment; Regulation FD; Exhibits | View | |
| 2026-09-29 | Other Events; Exhibits | View | |
| 2026-08-26 | Officer/Director Change | View | |
| 2026-08-18 | Regulation FD; Exhibits | View | |
| 2026-08-07 | Earnings Release; Regulation FD; Exhibits | View | |
| 2026-07-31 | Material Agreement; Exhibits | Agreement | View |
| 2026-06-23 | Regulation FD; Exhibits | View | |
| 2026-06-17 | Material Agreement; Unregistered Equity Sales; Exhibits | Agreement | View |
| 2026-05-28 | Officer/Director Change; Other Events; Exhibits | View | |
| 2026-05-14 | Material Agreement; Exhibits | Agreement | View |
| 2026-05-12 | Earnings Release; Regulation FD; Exhibits | View | |
| 2026-04-16 | Material Agreement; Exhibits | Agreement | View |
| 2026-03-27 | Earnings Release; Regulation FD; Exhibits | View | |
| 2026-02-27 | Other Events; Financial Statements and Exhibits | View | |
| 2026-02-17 | Entry into Material Definitive Agreement; Departure/Election of Directors; Appointment of Officers; | Agreement | View |
| 2026-02-02 | Entry into Material Definitive Agreement; Other Events; Financial Statements and Exhibits | Agreement | View |
| 2026-01-06 | Submission of Matters to a Vote of Security Holders; Regulation FD Disclosure; Financial Statements | View | |
| 2025-12-16 | Changes in Registrant's Certifying Accountant; Financial Statements and Exhibits | View | |
| 2025-11-21 | Regulation FD Disclosure; Other Events; Financial Statements and Exhibits | View | |
| 2025-11-21 | Notice of Delisting or Transfer | View |
Data extracted from SEC EDGAR 8-K filings using NLP. Relationships are as disclosed in filing text.
Covers 2021–2026. View on SEC EDGAR